Related Experiment Video
Updated: Mar 24, 2026
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
New Translational Research in the Medical Management of Orbital Melanoma
Lora Dagi Glass1, Ryan Sullivan2, Suzanne K Freitag1
1a Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , Massachusetts , USA and.
Abstract:
New translational research has paved the way for more optimistic management of melanoma. Medications targeting oncogenic signaling cascades and immune regulatory molecules have significantly improved overall survival for patients with metastatic melanoma. While isolated, operable orbital melanoma may still benefit from surgery, there potentially is an opportunity to provide patients with neoadjuvant systemic therapy with sustainable long-term effects. Additionally, patients with non-resectable orbital melanoma can benefit from systemic treatment.
Insights
New melanoma treatments targeting cancer pathways and immune responses offer hope for metastatic disease. Systemic therapies may provide long-term benefits for orbital melanoma, even in non-resectable cases.
Area of Science:
- Oncology
- Translational Research
- Ophthalmology
Background:
- Metastatic melanoma management has advanced significantly.
- Targeted therapies and immunotherapies have improved survival rates.
- Orbital melanoma presents unique management challenges.
Purpose of the Study:
- To explore the role of neoadjuvant systemic therapy in operable orbital melanoma.
- To highlight the benefits of systemic treatment for non-resectable orbital melanoma.
- To discuss optimistic management strategies for orbital melanoma.
Main Methods:
- Review of recent translational research in melanoma treatment.
- Analysis of systemic therapies targeting oncogenic signaling and immune regulation.
- Evaluation of treatment outcomes for orbital melanoma.
Main Results:
- Systemic therapies targeting oncogenic signaling cascades show promise.
- Immune regulatory molecule targeting has improved overall survival.
- Neoadjuvant systemic therapy may offer sustainable long-term effects for operable cases.
- Systemic treatment is beneficial for patients with non-resectable orbital melanoma.
Conclusions:
- Translational research offers new hope for melanoma management.
- Systemic therapies are crucial for advanced and non-resectable orbital melanoma.
- Neoadjuvant systemic therapy is a potential strategy for improving long-term outcomes.
